Bicara Therapeutics Inc. (BCAX) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US0554771032
Bicara Therapeutics Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -155.60 m USD |
| EBIT | -155.60 m USD |
| Net income | -137.95 m USD |
| Diluted EPS – continuing operations | -2.52 USD |
Full history since 2022, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
More stocks
- Patrizia (PAT.DE)
- Ls Invest (IFA.HM)
- Momentum Group AB (MMGR B.ST)
- Mingchen Health Co Ltd Class A (002919.SZ)
- Winstek Semiconductor Co Ltd (3265.TWO)
- Basler Kantonalbank (BSKP.SW)
- Zhongjie (Jiangsu) Technology Co.Ltd. (301072.SZ)
- SGL Carbon (SGL.DE)
- i3 Verticals, Inc. (IIIV)
- PARADISE LTD (034230.KS)
- Zambal Spain SOCIMI SA (YZBL.MC)
- Sunmax Biotechnology Co Ltd (4728.TWO)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.